Skip to NavigationSkip to content

Galen boosted by $295m Sarafem purchase

Published on 27/10/03 at 10:28am

Galen has bolstered its product range by buying the rights to pre-menstrual syndrome treatment Sarafem from Lilly for $295 million.

Shares in the Northern Ireland-based company rose sharply on the news, which confirmed its determination to expand its product range, currently focused on women health.

Launched in 2000, Sarafem is a reformulation of fluoxetine (Prozac) and generated sales of around $85 million in 2001.

Chief Executive Roger Boissoneault said: "This is an excellent addition to Galen women healthcare franchise in the US, where it will complement our existing range. The increasing awareness of pre-menstrual dysphoric disorder (PMDD) amongst the medical community presents us with a great opportunity to develop this recently launched product."

The company bought Duricef, a cephalosporin antibiotic, and Moisturel, a skin moisturising cream, from Bristol-Myers Squibb for $40 million. Its acquisition of Warner Chilcott in 2000 has given the company a sales base in the highly lucrative US market, where it hopes most Sarafem sales will be made.


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches